Your browser doesn't support javascript.
loading
Cuproptosis: A novel therapeutic target for overcoming cancer drug resistance.
Wang, Yumin; Chen, Yongming; Zhang, Junjing; Yang, Yihui; Fleishman, Joshua S; Wang, Yan; Wang, Jinhua; Chen, Jichao; Li, Yuanfang; Wang, Hongquan.
Affiliation
  • Wang Y; Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing 100049, PR China. Electronic address: 721wangym@aliyun.com.
  • Chen Y; State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, PR China.
  • Zhang J; Department of Hepato-Biliary Surgery, Department of Surgery, Huhhot First Hospital, Huhhot 010030, PR China.
  • Yang Y; Beijing Key Laboratory of Drug Target and Screening Research, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, PR China.
  • Fleishman JS; Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, NY 11439, USA.
  • Wang Y; Hunan Provincial Key Laboratory of Hepatobiliary Disease Research & Division of Hepato-Biliary-Pancreatic Surgery, Department of Surgery, The Second Xiangya Hospital of Central South University, Changsha 410011, PR China.
  • Wang J; Beijing Key Laboratory of Drug Target and Screening Research, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, PR China.
  • Chen J; Department of Respiratory and Critical Care Medicine, Aerospace Center Hospital, Peking University Aerospace School of Clinical Medicine, Beijing 100049, PR China.
  • Li Y; State Key Laboratory of Oncology in South China, Sun Yat-Sen University Cancer Center, Guangzhou, PR China. Electronic address: liyuanf@sysucc.org.cn.
  • Wang H; Department of Neurology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, PR China. Electronic address: whongquan@alu.fudan.edu.cn.
Drug Resist Updat ; 72: 101018, 2024 Jan.
Article in En | MEDLINE | ID: mdl-37979442
Cuproptosis is a newly identified form of cell death driven by copper. Recently, the role of copper and copper triggered cell death in the pathogenesis of cancers have attracted attentions. Cuproptosis has garnered enormous interest in cancer research communities because of its great potential for cancer therapy. Copper-based treatment exerts an inhibiting role in tumor growth and may open the door for the treatment of chemotherapy-insensitive tumors. In this review, we provide a critical analysis on copper homeostasis and the role of copper dysregulation in the development and progression of cancers. Then the core molecular mechanisms of cuproptosis and its role in cancer is discussed, followed by summarizing the current understanding of copper-based agents (copper chelators, copper ionophores, and copper complexes-based dynamic therapy) for cancer treatment. Additionally, we summarize the emerging data on copper complexes-based agents and copper ionophores to subdue tumor chemotherapy resistance in different types of cancers. We also review the small-molecule compounds and nanoparticles (NPs) that may kill cancer cells by inducing cuproptosis, which will shed new light on the development of anticancer drugs through inducing cuproptosis in the future. Finally, the important concepts and pressing questions of cuproptosis in future research that should be focused on were discussed. This review article suggests that targeting cuproptosis could be a novel antitumor therapy and treatment strategy to overcome cancer drug resistance.
Subject(s)
Key words

Full text: 1 Database: MEDLINE Main subject: Copper / Neoplasms Limits: Humans Language: En Journal: Drug Resist Updat Journal subject: ANTINEOPLASICOS Year: 2024 Type: Article

Full text: 1 Database: MEDLINE Main subject: Copper / Neoplasms Limits: Humans Language: En Journal: Drug Resist Updat Journal subject: ANTINEOPLASICOS Year: 2024 Type: Article